Iridex (IRIX) risk factors, FY2025 10-K

Iridex's FY2025 10-K, filed Apr 02, 2026. The risk counts for this filing are not shown yet. The filing itself is linked below.

Open IRIX in Gloom →
Iridex's chart, financials and news, free in your browser.Open IRIX in Gloom →

Iridex's biggest risks in the FY2025 10-K

  • International revenue heavily depends on the Netherlands at 14.7 percent and China at 11.0 percent for fiscal year 2025.
  • Diluted share counts and convertible debt obligations from Novel impact net loss calculations.
  • Financial reporting relies on internal controls with inherent limitations.

The risks most specific to Iridex

  • Revenues are attributed to countries based on location of end customers

    The Netherlands and China represent significant international revenue streams at 14.7 percent and 11.0 percent respectively for fiscal year 2025.

  • 16. Computation of Basic and Diluted Net Loss Per Common Share

    The company reported a net loss of 4,437 thousand dollars for the twelve months ended January 3, 2026.

  • For the twelve months ended January 3, 2026 and December 28, 2024 , potential shares from the conversion of Novel's convertible debt and preferred stock totaling 5,000,000 and 0 , respectively, were excluded from the computation of diluted weighted average shares outstanding

    Potential shares from Novel's convertible debt and preferred stock totaled 5,000,000 for the period ending January 3, 2026.

  • Management’s Report on Internal Control over Financial Reporting

    Internal financial reporting controls carry inherent limitations including human error and potential circumvention.

Risk factor headings as read

Headings as the filing states them, in filing order.

Other

  1. 0115. Business Segments and Geographical Information
  2. 02Revenues are attributed to countries based on location of end customers
  3. 0316. Computation of Basic and Diluted Net Loss Per Common Share
  4. 04For the twelve months ended January 3, 2026 and December 28, 2024 , potential shares from the conversion of Novel's convertible debt and preferred stock totaling 5,000,000 and 0 , respectively, were excluded from the computation of diluted weighted average shares outstanding
  5. 05Evaluation of Disclosure Controls and Procedures
  6. 06Management’s Report on Internal Control over Financial Reporting
  7. 07Changes in Internal Control over Financial Reporting
  8. 08Inherent Limitations on Effectiveness of Controls
  9. 09Securities Trading Plans of Directors and Executive Officers
  10. 10I tem 10. Directors, Executive Officers and Corporate Governance
  11. 11I tem 15. Exhibits and Financial Statement Schedules
  12. 12Cover Page formatted as Inline XBRL and contained in Exhibit 101
  13. 13Trademark Acknowledgments

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.